Triple negative breast cancer is a type of breast cancer defined by the absence of three important markers commonly found in other breast cancers. These tumors test negative for estrogen receptors, progesterone receptors, and the HER2 protein or gene. Because all three markers are missing, the disease is called “triple negative.” These receptors are often targets for hormonal or HER2-directed therapies, so when they are not present, those treatment options are not effective.
Triple negative breast cancer is generally considered more aggressive and more active than hormone receptor–positive or HER2-positive breast cancers. In many cases, it carries a higher risk of recurrence and a less favorable prognosis. However, not all triple negative cancers behave the same way. Some respond extremely well to chemotherapy, while others may be less sensitive, and doctors often determine responsiveness only after treatment begins.
This type of breast cancer is more frequently seen in individuals with inherited BRCA1 gene mutations. BRCA mutations can be passed down from either parent and significantly increase cancer risk. Triple negative breast cancer is also more common in younger patients, particularly those under age 40, and occurs at higher rates among Black women. Overall, about 10% of all breast cancers are triple negative, though the percentage is closer to 20% in Black women. Current understanding suggests environmental and social factors likely contribute to this difference rather than biological causes alone.
Surgery remains an important part of treatment. Patients may undergo breast-conserving surgery, such as a lumpectomy, or a mastectomy depending on tumor size, breast size, personal preference, or genetic risk factors. Having triple negative breast cancer does not automatically require mastectomy. Individuals with inherited mutations may choose bilateral mastectomy to reduce future cancer risk. Evaluation of lymph nodes is always performed, typically through sentinel lymph node biopsy, even when imaging appears normal, because lymph node status helps determine cancer stage and guides treatment decisions.
Radiation therapy is commonly used after breast-conserving surgery to lower the risk of recurrence. It may also be recommended after mastectomy in cases involving large tumors or cancer spread to lymph nodes. Radiation helps reduce the chance of cancer returning in the treated area.
Systemic treatment, which affects the entire body, plays a central role in managing triple negative breast cancer. Unlike other breast cancer types, hormonal therapies and HER2-targeted drugs are not effective because the required receptors are absent. As a result, chemotherapy becomes the primary systemic treatment alongside surgery and radiation.
Chemotherapy is often given before surgery, a strategy known as neoadjuvant therapy. This approach can shrink tumors, sometimes making surgery less extensive, and allows doctors to evaluate how well the cancer responds to treatment. Even when imaging shows major tumor shrinkage or disappearance, surgery is still recommended because microscopic cancer cells may remain. After surgery, additional therapy decisions depend on how much cancer is found in the removed tissue.
If significant cancer remains after pre-surgical chemotherapy, additional medications may be recommended. Capecitabine is an oral chemotherapy drug often used for patients with higher-risk residual disease. Patients with BRCA1 mutations may also receive olaparib, an oral targeted therapy taken for up to a year to reduce recurrence risk.
Immunotherapy has become an important advancement in treating triple negative breast cancer. These treatments stimulate the body’s immune system to recognize and attack cancer cells. A commonly used immunotherapy drug is given intravenously alongside chemotherapy before surgery and may continue afterward on its own if residual disease remains. Immunotherapy can produce strong tumor responses but may also cause immune-related side effects affecting normal organs, in addition to standard chemotherapy effects.
Because of its association with inherited mutations, individuals diagnosed with triple negative breast cancer are often encouraged to undergo genetic counseling and testing. Genetic results can influence treatment choices, guide preventive strategies, and provide important information for family members.
Although triple negative breast cancer can be more aggressive, modern treatment approaches combining surgery, chemotherapy, radiation, targeted therapy, and immunotherapy have significantly improved outcomes. Care is highly individualized, and treatment plans are adjusted based on tumor response, genetic findings, and overall patient health.
